

Abstract

The present invention provides a new type of pharmaceutical agent that recovers corneal sensitivity after 5 corneal surgery or improves the condition of dry eye. Application of a somatostatin receptor agonist is expected to provide an improvement effect on decreased corneal sensitivity after cataract surgery or LASIK surgery, decreased corneal sensitivity and dry eye associated with corneal 10 neurodegeneration such as neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like.